Recent events
Recent events tied to this brand in public sources.
Back to profile9 entries
2026
Samsung Biologics signs $262 million manufacturing deal with European pharma company
Samsung Biologics signed a $262 million contract manufacturing deal with a European pharmaceutical company, as reported on September 11, 2026.
2021
Samsung Group announces a $205 billion expansion plan
Samsung Group unveiled a 240 trillion won ($205 billion) expansion plan covering three years and said it would entail hiring 40,000 people. The plan includes 180 trillion won allocated to South Korea.
2020
Samsung Biologics appoints John Rim as CEO
Samsung Biologics appointed John Rim as chief executive officer, replacing former CEO Kim Tae-han.
2020
Samsung Biologics wins Best Digital Campaign award
Samsung Biologics' Virtual Exhibition Hall won the Best Digital Campaign award during Digital Pharma Innovation Week.
2020
PharmAbcine and Samsung Biologics partner on PMC-403
PharmAbcine entered into a strategic partnership with Samsung Biologics for development and manufacturing of its PMC-403 antibody candidate. Samsung Biologics will provide contract development and manufacturing services, including cell line and process development, clinical manufacturing, and IND filing support.
2020
GSK and Samsung Biologics agree on biopharmaceutical manufacturing capacity
GSK and Samsung Biologics announced a deal under which Samsung Biologics will provide GSK with flexible capacity for large-scale biopharmaceutical manufacturing. The agreement initially covers commercial production of Benlysta, with technology transfer starting in 2020 and first commercial supply expected in 2022.
2020
GSK and Samsung Biologics enter manufacturing partnership
GSK and Samsung Biologics entered a partnership under which Samsung Biologics will provide additional manufacturing capacity for GSK's biopharmaceutical therapies. The agreement is worth more than $231 million over eight years and initially covers commercial production of Benlysta.
2020
Vir Biotechnology and Samsung Biologics agree on antibody manufacturing
Vir Biotechnology and Samsung Biologics announced a manufacturing agreement valued at approximately US$362 million under which Samsung Biologics will provide large-scale manufacturing services for Vir's SARS-CoV-2 monoclonal antibody program. Production was scheduled to commence in October 2020; the parties were still negotiating complete details and hoped to execute a definitive agreement before July 31, 2020.
2020
Samsung Biologics reports FY2019 earnings growth
Samsung Biologics reported that FY2019 sales grew 30.9% to 701.6 billion won and operating profit grew 64.6% to 91.7 billion won compared with the previous year.